ArticleJACC. Case reports2026
Bortezomib-Induced Myocarditis in a Patient With Multiple Myeloma.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBortezomib is a reversible proteasome inhibitor used as first-line therapy for multiple myeloma and mantle cell lymphoma. Although effective, it can in rare cases cause cardiotoxicity, including myocarditis. CASE SUMMARY: A 58-year-old man with multiple myeloma (MC I, lambda light chain type) developed progressive dyspnea and edema after VTD (bortezomib, thalidomide, dexamethasone) therapy. Echocardiography showed severe left ventricular systolic dysfunction (left ventricular ejection fraction: 35%, global longitudinal strain: -10%) with elevated troponin I (3,176 ng/L). Coronary computed tomography angiography ruled out ischemia, and cardiac magnetic resonance imaging confirmed extensive acute myocarditis. Bortezomib was discontinued and guideline-directed heart failure therapy was initiated, resulting in complete clinical and echocardiographic recovery (left ventricular ejection fraction: 52%, global longitudinal strain: -17%) within 3 weeks. DISCUSSION: Bortezomib-induced myocarditis is extremely rare. Proposed mechanisms include proteasome inhibition-induced endoplasmic reticulum stress, mitochondrial dysfunction, and impaired NF-κB signaling. TAKE-HOME MESSAGE: Early recognition, prompt drug withdrawal, and timely heart failure therapy are essential to ensure full recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.